Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 2	2025-11-10		NCT02253316

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Millennium Pharmaceuticals, Inc.	9
Multiple Myeloma Research Consortium	9
Washington University School of Medicine	475

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope	Duarte	United States	238
Colorado Blood Cancer Institute	Denver	United States	178
Emory University - Winship Cancer Institute	Atlanta	United States	11
Icahn School of Medicine at Mount Sinai	New York	United States	342
Karmanos Cancer Institute	Detroit	United States	153
Mayo Clinic	Rochester	United States	664
Ohio State University Comprehensive Cancer Center	Columbus	United States	548
Tennessee Oncology, PLLC	Nashville	United States	30
University of California, San Francisco	San Francisco	United States	294
Washington University School of Medicine	St Louis	United States	1